Promomed Group of Companies and the Moscow Department of Investment and Industrial Policy have signed an agreement on the development of biotechnologies

Today, within the framework of the XXVI St. Petersburg International Economic Forum (SPIEF), the Promomed Group of Companies signed a cooperation Agreement with the Department of Investment and Industrial Policy of the City of Moscow in the interests of developing new high-tech sectors of the economy, creating new jobs in modern high-tech industries and innovative companies.

This Agreement provides for the creation of conditions for Artsellens, a member of Promomed Group of Companies, to conduct industrial and production activities in the Technopolis Moscow special economic zone. At the site of the Pechatniki Technopolis, the company plans to create a modern research laboratory with a pilot production site for the development of new drugs, including original ones, and scaling technological processes, and the production of original domestic biological products will be created at the Alabushevo site.

"With the support of the Moscow Government, Promomed Group is creating a full-cycle center for the production of new-generation biotechnological drugs at Technopolis. This is where we plan to develop our new line of biotechnological substances., – commented on the Agreement Peter the White, Chairman of the Board of Directors of Promomed Group of Companies. – We are very grateful to the Moscow Government and personally to the Mayor of Moscow Sergey Semenovich Sobyanin for the support of this project, which is fundamentally important for Russian medicine. For drug independence, we need our own innovative next-in-class and first-in-class medicines. They will be the ones who will move us forward. And the signing of today's agreement between the Moscow Government and Promomed Group of Companies is a significant step in this direction. We will do everything in our power to ensure that the latest biopharmaceuticals are adopted by the country's doctors as soon as possible and strengthen the export potential of our Homeland.".

Vladislav Ovchinsky, head of the Department of Investment and Industrial Policy of the City of Moscow, said: "The new production facility will become part of the pharmaceutical cluster of the special economic zone. The research unit will be located at the Pechatniki site, and the production will be located at Alabushevo. A plot of 3.2 hectares has been allocated for the construction of the enterprise. It is planned to create more than 400 jobs. Investments in the project will amount to about 4.3 billion rubles".

The project will begin with the release of biosimilars of technologically complex foreign drugs for the treatment of vital diseases. At the second stage, a technological base will be created for the development of original domestic biological products.

For reference:

The Artsellens company (part of Promomed Group of Companies) is engaged in research, development and production of medicines. Founded in 2023, it is the successor of biotechnological production based on the Biochemist plant (Saransk).

The area of the Pechatniki research unit is 4,700 m.², the production site in the SEZ "Alabushevo" is 3.2 hectares.

The total production capacity at Artsellens is estimated at 150 kg of the substance per year, or about 750,000 vials of the drug. It is planned that at the first stage, the capacity of the pilot production site will be about 250 thousand vials of the drug per year.

The project will create over 400 new highly qualified jobs: at least 115 at the Pechatniki site, and at least 295 at the Alabushevo site.